Survivin isoform Delta Ex3 regulates tumor spheroid formation

Cancer Letters

Volumn 318, Issue 1, 2012, Pages 61-67

  Espinosa, Magali ^a   Ceballos Cancino, Gisela ^a   Callaghan, Richard ^c   Maldonado, Vilma ^b   Patiño, Nelly ^a   Ruíz, Víctor ^d   Meléndez Zajgla, Jorge ^a  

^a INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

Apoptosis; Cancer; Spheroid; Survivin

Indexed keywords

SURVIVIN; SURVIVIN DETLTA EX3; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; HELA CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVIN DELTA EX3 GENE; TUMOR SPHEROID; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; HELA CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; INHIBITOR OF APOPTOSIS PROTEINS; PROTEIN ISOFORMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SPHEROIDS, CELLULAR;

INTRACISTERNAL A-PARTICLES;

EID: 84857140103     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.12.002     Document Type: Article

References (36)

1. Altieri D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22:8581-8589.
2. Mita A.C., Mita M.M., Nawrocki S.T., Giles F.J. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. 2008, 14:5000-5005.
3. Verdecia M.A., Huang H., Dutil E., Kaiser D.A., Hunter T., Noel J.P. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat. Struct. Biol. 2000, 7:602-608.
4. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997, 3:917-921.
5. Zheng W., Ma X., Wei D., Wang T., Ma Y., Yang S. Molecular cloning and bioinformatics analysis of a novel spliced variant of survivin from human breast cancer cells. DNA Seq. 2005, 16:321-328.
6. Mahotka C., Wenzel M., Springer E., Gabbert H.E., Gerharz C.D. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999, 59:6097-6102.
7. Badran A., Yoshida A., Ishikawa K., Goi T., Yamaguchi A., Ueda T., Inuzuka M. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem. Biophys. Res. Commun. 2004, 314:902-907.
8. Caldas H., Honsey L.E., Altura R.A. Survivin 2alpha: a novel survivin splice variant expressed in human malignancies. Mol. Cancer 2005, 4:11.
9. Knauer S.K., Bier C., Schlag P., Fritzmann J., Dietmaier W., Rodel F., Klein-Hitpass L., Kovacs A.F., Doring C., Hansmann M.L., Hofmann W.K., Kunkel M., Brochhausen C., Engels K., Lippert B.M., Mann W., Stauber R.H. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 2007, 6:1502-1509.
10. O'Connor D.S., Grossman D., Plescia J., Li F., Zhang H., Villa A., Tognin S., Marchisio P.C., Altieri D.C. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc. Natl. Acad. Sci. USA 2000, 97:13103-13107.
11. Wall N.R., O'Connor D.S., Plescia J., Pommier Y., Altieri D.C. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res. 2003, 63:230-235.
12. Takashima H., Nakajima T., Moriguchi M., Sekoguchi S., Nishikawa T., Watanabe T., Katagishi T., Kimura H., Minami M., Itoh Y., Kagawa K., Okanoue T. In vivo expression patterns of survivin and its splicing variants in chronic liver disease and hepatocellular carcinoma. Liver Int. 2005, 25:77-84.
13. Nakano J., Huang C., Liu D., Masuya D., Yokomise H., Ueno M., Haba R., Sumitomo S. The clinical significance of splice variants and subcellular localisation of survivin in non-small cell lung cancers. Brit. J. Cancer 2008, 98:1109-1117.
14. Sarela A.I., Macadam R.C., Farmery S.M., Markham A.F., Guillou P.J. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000, 46:645-650.
15. Monzo M., Rosell R., Felip E., Astudillo J., Sanchez J.J., Maestre J., Martin C., Font A., Barnadas A., Abad A. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol. 1999, 17:2100-2104.
16. Ikeguchi M., Kaibara N. Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Brit. J. Cancer 2002, 87:883-887.
17. Ren Y.J., Zhang Q.Y. Expression of survivin and its clinical significance in non-small cell lung cancer. Beijing Da Xue Xue Bao 2005, 37:504-507.
18. Noton E.A., Colnaghi R., Tate S., Starck C., Carvalho A., Ko Ferrigno P., Wheatley S.P. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J. Biol. Chem. 2006, 281:1286-1295.
19. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 2008, 8:61-70.
20. Trabulo S., Cardoso A.M., Santos-Ferreira T., Cardoso A.L., Simoes S., Pedroso de Lima M.C. Survivin silencing as a promising strategy to enhance the sensitivity of cancer cells to chemotherapeutic agents. Mol. Pharm. 2011, 8:1120-1131.
21. Montazeri Aliabadi H., Landry B., Mahdipoor P., Uludag H. Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line. Mol. Pharm. 2011, 8:1821-1830.
22. Nakahara T., Yamanaka K., Hatakeyama S., Kita A., Takeuchi M., Kinoyama I., Matsuhisa A., Nakano K., Shishido T., Koutoku H., Sasamata M. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs 2011, 22:454-462.
23. Kenny G.D., Kamaly N., Kalber T.L., Brody L.P., Sahuri M., Shamsaei E., Miller A.D., Bell J.D. Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo. J. Control Release 2011, 149:111-116.
24. Yuhas J.M., Tarleton A.E., Molzen K.B. Multicellular tumor spheroid formation by breast cancer cells isolated from different sites. Cancer Res. 1978, 38:2486-2491.
25. Ceballos-Cancino G., Espinosa M., Maldonado V., Melendez-Zajgla J. Regulation of mitochondrial Smac/DIABLO-selective release by survivin. Oncogene 2007, 26:7569-7575.
26. Mendoza J., Zamora R., Gallardo J.C., Ceballos G., Aldana A., Espinosa M., Maldonado V., Melendez-Zajgla J. NF-kappaB does not influence the induction of apoptosis by Ukrain. Cancer Biol. Ther. 2006, 5:788-793.
27. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267:1456-1462.
28. Grossman D., McNiff J.M., Li F., Altieri D.C. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J. Invest. Dermatol. 1999, 113:1076-1081.
29. Adida C., Recher C., Raffoux E., Daniel M.T., Taksin A.L., Rousselot P., Sigaux F., Degos L., Altieri D.C., Dombret H. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Brit. J. Haematol. 2000, 111:196-203.
30. Espinosa M., Cantu D., Herrera N., Lopez C.M., De la Garza J.G., Maldonado V., Melendez-Zajgla J. Inhibitors of apoptosis proteins in human cervical cancer. BMC Cancer 2006, 6:45.
31. Caldas H., Jiang Y., Holloway M.P., Fangusaro J., Mahotka C., Conway E.M., Altura R.A. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005, 24:1994-2007.
32. Dohi T., Beltrami E., Wall N.R., Plescia J., Altieri D.C. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J. Clin. Invest. 2004, 114:1117-1127.
33. Sutherland R.M. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988, 240:177-184.
34. Brown J.M., Giaccia A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998, 58:1408-1416.
35. Islam A., Kageyama H., Hashizume K., Kaneko Y., Nakagawara A. Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin-beta/2B. Med. Pediatr. Oncol. 2000, 35:550-553.
36. Barrett R.M., Osborne T.P., Wheatley S.P. Phosphorylation of survivin at threonine 34 inhibits its mitotic function and enhances its cytoprotective activity. Cell Cycle 2009, 8:278-283.